Compare IPST & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPST | AEMD |
|---|---|---|
| Founded | 2011 | 1984 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Beverages (Production/Distribution) | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8M | 2.1M |
| IPO Year | N/A | 2008 |
| Metric | IPST | AEMD |
|---|---|---|
| Price | $2.45 | $0.71 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $164.00 | $15.00 |
| AVG Volume (30 Days) | 22.2K | ★ 225.3K |
| Earning Date | 04-14-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $70.16 | N/A |
| Revenue Next Year | $60.33 | N/A |
| P/E Ratio | $0.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.24 | $0.51 |
| 52 Week High | $15.08 | $5.89 |
| Indicator | IPST | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 24.27 |
| Support Level | $0.43 | $0.51 |
| Resistance Level | $3.95 | $0.83 |
| Average True Range (ATR) | 0.30 | 0.16 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 27.03 | 5.41 |
IP Strategy Holdings Inc operate a diversified business centered on digital asset-based infrastructure and intellectual property (IP) management, supplemented by a legacy craft spirits operating segment. The Company provides public market investors with broad exposure to the around $80 trillion programmable intellectual property economy in a regulated equity format. Its treasury reserve of $IP tokens provides direct participation in the Story ecosystem, which enables on-chain registration, licensing, and monetization of intellectual property.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.